Ledger.Open graph →
SEC Form D · Amendment · filed May 5, 2022

Ansa Biotechnologies, Inc

Offering
$76.7M
Sold
$68.0M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
Emeryville, CA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (9)

Daniel T. Lin-Arlow · Emeryville, CAExec · DirectorSebastian T. Palluk · Emeryville, CAExec · DirectorLily Li · Emeryville, CADirectorRicardo Repenning · Cambridge, MADirectorYmir Vigfusson · DOVER, DEExec · DirectorRichard Chesney · Dallas, TXExec · DirectorNewton Howard · FRISCO, TXExec · DirectorRobert V. Delaney, Jr · New York, NYExec · DirectorBrian P. Cassidy · New York, NYDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗

Ansa Biotechnologies, Inc. — SEC Form D filing (2022) | Ledger